{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:17:20Z","timestamp":1791940640267,"version":"4.3.4"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA261978"],"award-info":[{"award-number":["1R01CA261978"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5P30CA016672"],"award-info":[{"award-number":["5P30CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials Communications"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.conctc.2022.100943","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T02:14:00Z","timestamp":1655086440000},"page":"100943","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["An overview of the BOIN design and its current extensions for novel early-phase oncology trials"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1730-3756","authenticated-orcid":false,"given":"Revathi","family":"Ananthakrishnan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruitao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunsheng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"LaValley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.conctc.2022.100943_bib1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1200\/CCI.20.00122","article-title":"BOIN suite: a software platform to design and implement novel early-phase clinical trials","volume":"5","author":"Zhou","year":"2021","journal-title":"JCO Clin Cancer Inform"},{"issue":"2","key":"10.1016\/j.conctc.2022.100943_bib2","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1158\/1078-0432.CCR-18-0203","article-title":"The impact of early-phase trial design in the drug development process","volume":"25","author":"Conaway","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.conctc.2022.100943_bib3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.cct.2017.04.006","article-title":"A Bayesian interval dose-finding design addressing Ockham's razor: mTPI-2","volume":"58","author":"Guo","year":"2017","journal-title":"Contemp. Clin. Trials"},{"issue":"15","key":"10.1016\/j.conctc.2022.100943_bib4","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1158\/1078-0432.CCR-17-0220","article-title":"A novel bayesian toxicity probability interval design for phase I clinical trials","volume":"23","author":"Yan","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"18","key":"10.1016\/j.conctc.2022.100943_bib5","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1158\/1078-0432.CCR-18-0168","article-title":"Accuracy, safety, and reliability of novel phase I trial designs","volume":"24","author":"Zhou","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.conctc.2022.100943_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2019.100379","article-title":"Evaluating the effects of design parameters on the performances of phase I trial designs","volume":"15","author":"Zhu","year":"2019","journal-title":"Contemp Clin Trials Commun"},{"key":"10.1016\/j.conctc.2022.100943_bib7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.conctc.2018.08.010","article-title":"Overall success rate of a safe and efficacious drug: results using six phase 1 designs, each followed by standard phase 2 and 3 designs","volume":"12","author":"Ruppert","year":"2018","journal-title":"Contemp Clin Trials Commun"},{"issue":"2","key":"10.1016\/j.conctc.2022.100943_bib8","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/sim.7043","article-title":"Performance of toxicity probability interval based designs in contrast to the continual reassessment method","volume":"36","author":"Horton","year":"2017","journal-title":"Stat. Med."},{"key":"10.1016\/j.conctc.2022.100943_bib9","series-title":"On the Interval-Based Dose-Finding Designs","author":"Ji","year":"2017"},{"issue":"17","key":"10.1016\/j.conctc.2022.100943_bib10","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1158\/1078-0432.CCR-16-0592","article-title":"Bayesian optimal interval design: a simple and well-performing design for phase I oncology trials","volume":"22","author":"Yuan","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.conctc.2022.100943_bib11","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/rssc.12089","article-title":"Bayesian optimal interval designs for phase 1 clinical trials","volume":"64","author":"Liu","year":"2015","journal-title":"J. Roy. Stat. Soc. C Appl. Stat."},{"issue":"2","key":"10.1016\/j.conctc.2022.100943_bib12","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.37563","article-title":"Evaluation of deviation from planned cohort size and operating characteristics of phase 1 trials","volume":"4","author":"Park","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.conctc.2022.100943_bib13","series-title":"Statistical Inference under Order Restrictions; the Theory and Application of Isotonic Regression (No. 04; QA278. 7, B3.)","author":"Barlow","year":"1972"},{"issue":"13","key":"10.1016\/j.conctc.2022.100943_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v094.i13","article-title":"BOIN: an R package for designing single-agent and drug-combination dose-finding trials using bayesian optimal interval designs","volume":"94","author":"Yan","year":"2020","journal-title":"J. Stat. Software"},{"issue":"4","key":"10.1016\/j.conctc.2022.100943_bib15","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/biom.12912","article-title":"Bayesian optimal interval design with multiple toxicity constraints","volume":"74","author":"Lin","year":"2018","journal-title":"Biometrics"},{"key":"10.1016\/j.conctc.2022.100943_bib16","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/rssc.12263","article-title":"gBOIN: a unified model-assisted phase I trial design accounting for toxicity grades, and binary or continuous end points","volume":"68","author":"Mu","year":"2019","journal-title":"J. Roy. Stat. Soc. C"},{"key":"10.1016\/j.conctc.2022.100943_bib17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1198\/016214504000000043","article-title":"Dose-finding based on multiple toxicities in a soft tissue sarcoma trial","volume":"99","author":"Bekele","year":"2004","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.conctc.2022.100943_bib18","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/annonc\/mdr146","article-title":"Toxicity burden score: a novel approach to summarize multiple toxic effects","volume":"23","author":"Lee","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.conctc.2022.100943_bib19","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/sim.5737","article-title":"Dose-finding designs using a novel quasi-continuous endpoint for multiple toxicities","volume":"32","author":"Ezzalfani","year":"2013","journal-title":"Stat. Med."},{"key":"10.1016\/j.conctc.2022.100943_bib20","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.cct.2010.05.010","article-title":"A novel toxicity scoring system treating toxicity response as a quasi-continuous variable in phase i clinical trials","volume":"31","author":"Chen","year":"2010","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.conctc.2022.100943_bib21","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1200\/PO.20.00257","article-title":"BOIN12: Bayesian Optimal Interval Phase I\/II trial design for utility-based dose finding in immunotherapy and targeted therapies","volume":"4","author":"Lin","year":"2020","journal-title":"JCO Precis. Oncol."},{"issue":"20","key":"10.1016\/j.conctc.2022.100943_bib22","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1158\/1078-0432.CCR-18-0246","article-title":"Time-to-Event bayesian optimal interval design to accelerate phase I trials","volume":"24","author":"Yuan","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.conctc.2022.100943_bib23","series-title":"Handbook of Methods for Designing, Monitoring, and Analyzing Dose Finding Trials","first-page":"109","article-title":"Designing early-phase drug combination trials","author":"Yuan","year":"2017"},{"issue":"2","key":"10.1016\/j.conctc.2022.100943_bib24","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.2007.12.7712","article-title":"Shortening the timeline of pediatric phase I trials: the rolling six design","volume":"26","author":"Skolnik","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.conctc.2022.100943_bib25","first-page":"1","article-title":"Time-to-event model assisted designs to accelerate phase I clinical trials","author":"Lin","year":"2019","journal-title":"Biostatistics"},{"issue":"2","key":"10.1016\/j.conctc.2022.100943_bib26","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/pst.2182","article-title":"TITE-gBOIN: time-to-event Bayesian optimal interval design to accelerate dose-finding accounting for toxicity grades","volume":"21","author":"Takeda","year":"2022","journal-title":"Pharmaceut. Stat."},{"issue":"4","key":"10.1016\/j.conctc.2022.100943_bib27","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/pst.1864","article-title":"BOIN-ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes","volume":"17","author":"Takeda","year":"2018","journal-title":"Pharmaceut. Stat."},{"issue":"26","key":"10.1016\/j.conctc.2022.100943_bib28","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1002\/sim.7428","article-title":"STEIN: a simple toxicity and efficacy interval design for seamless phase I\/II clinical trials","volume":"36","author":"Lin","year":"2017","journal-title":"Stat. Med."},{"issue":"5","key":"10.1016\/j.conctc.2022.100943_bib29","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1177\/0962280215594494","article-title":"Bayesian optimal interval design for dose finding in drug-combination trials","volume":"26","author":"Lin","year":"2017","journal-title":"Stat. Methods Med. Res."},{"issue":"3","key":"10.1016\/j.conctc.2022.100943_bib30","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/j.0006-341X.2004.00218.x","article-title":"Dose-finding based on efficacy-toxicity trade-offs","volume":"60","author":"Thall","year":"2004","journal-title":"Biometrics"},{"issue":"6","key":"10.1016\/j.conctc.2022.100943_bib31","first-page":"516\u2010532","article-title":"An adaptive dose\u2010finding method using a change\u2010point model for molecularly targeted agents in phase I trials","volume":"31","author":"Sato","year":"2016","journal-title":"Stat. Med."},{"key":"10.1016\/j.conctc.2022.100943_bib32","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-Update and clarification: from the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.conctc.2022.100943_bib33","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-16-1125","article-title":"Toxicity and efficacy probability interval design for phase I adoptive cell therapy dose-finding clinical trials","volume":"23","author":"Li","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"28","key":"10.1016\/j.conctc.2022.100943_bib34","doi-asserted-by":"crossref","first-page":"5299","DOI":"10.1002\/sim.8361","article-title":"A utility-based Bayesian optimal interval (U-BOIN) phase I\/II design to identify the optimal biological dose for targeted and immune therapies","volume":"38","author":"Zhou","year":"2019","journal-title":"Stat. Med."},{"issue":"Suppl 1","key":"10.1016\/j.conctc.2022.100943_bib35","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1093\/jcag\/gwz047.089","article-title":"A90 A utility-based bayesian optimal interval (U-BOIN) phase I\/II design to identify the optimal biological dose for targeted and immune therapies","volume":"3","author":"Zhou","year":"2020","journal-title":"J. Can. Assoc. Gastroenterol."},{"key":"10.1016\/j.conctc.2022.100943_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/bimj.202100263","article-title":"gBOIN-ET: the generalized Bayesian optimal interval design for optimal dose-finding accounting for ordinal graded efficacy and toxicity in early clinical trials","author":"Takeda","year":"2022","journal-title":"Biom. J."},{"key":"10.1016\/j.conctc.2022.100943_bib37","article-title":"TITE-BOIN-ET: time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes","volume":"12","author":"Takeda","year":"2019","journal-title":"Pharmaceut. Stat."},{"issue":"4","key":"10.1016\/j.conctc.2022.100943_bib38","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1080\/10543406.2019.1632881","article-title":"On the relative efficiency of model-assisted designs: a conditional approach","volume":"29","author":"Lin","year":"2019","journal-title":"J. Biopharm. Stat."},{"issue":"11","key":"10.1016\/j.conctc.2022.100943_bib39","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/sim.9337","article-title":"TiTE-BOIN12: a Bayesian phase I\/II trial design to find the optimal biological dose with late-onset toxicity and efficacy","volume":"41","author":"Zhou","year":"2022","journal-title":"Stat. Med."},{"issue":"4","key":"10.1016\/j.conctc.2022.100943_bib40","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/j.0006-341X.2000.01177.x","article-title":"Sequential designs for phase I clinical trials with late-onset toxicities","volume":"56","author":"Cheung","year":"2000","journal-title":"Biometrics"},{"issue":"27","key":"10.1016\/j.conctc.2022.100943_bib41","doi-asserted-by":"crossref","first-page":"4924","DOI":"10.1002\/sim.7095","article-title":"A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials","volume":"35","author":"Zhang","year":"2016","journal-title":"Stat. Med."},{"key":"10.1016\/j.conctc.2022.100943_bib42","series-title":"JSM Proceedings, Biopharmaceutical Section","first-page":"4924","article-title":"A simple bayesian design to identify the maximum tolerated dose contour for drug combination trials","author":"Zhang","year":"2016"},{"issue":"506","key":"10.1016\/j.conctc.2022.100943_bib43","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/01621459.2014.881740","article-title":"Using data augmentation to facilitate conduct of phase I\u2013II clinical trials with delayed outcomes","volume":"109","author":"Jin","year":"2014","journal-title":"J. Am. Stat. Assoc."},{"issue":"1","key":"10.1016\/j.conctc.2022.100943_bib44","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1541-0420.2006.00666.x","article-title":"The continual reassessment method for multiple toxicity grades: a Bayesian quasi-likelihood approach","volume":"63","author":"Yuan","year":"2007","journal-title":"Biometrics"}],"container-title":["Contemporary Clinical Trials Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865422000606?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865422000606?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:05:37Z","timestamp":1762520737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451865422000606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":44,"alternative-id":["S2451865422000606"],"URL":"https:\/\/doi.org\/10.1016\/j.conctc.2022.100943","relation":{},"ISSN":["2451-8654"],"issn-type":[{"value":"2451-8654","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An overview of the BOIN design and its current extensions for novel early-phase oncology trials","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.conctc.2022.100943","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100943"}}